Article Text


234 Effectiveness of Fetal Perflurocarbon Therapy for Lung Hypoplasia in Diaphragmatic Hernia
  1. S Herber-Jonat1,
  2. A Vuckovic2,
  3. R Mittal1,
  4. J Jani3,
  5. AW Flemmer1
  1. 1Div. of Neonatology, University Children’s Hospital, LMU Munich, Munich, Germany
  2. 2Laboratory of Physiology and Physiopathology, Faculty of Medicine, Université Libre de Bruxelles
  3. 3Department of Obstetrics and Gynecology, CHU Brugmann, Brussel, Belgium


Aims To assess the effects of fetal, intratracheal perfluoroctylbromid (PFOB) instillation on lung-mechanics and gene expression of Surfactant and developmental proteins in a newborn rabbit model of lung hypoplasia.

Methods On day 23/31, diaphragmatic hernia was induced by fetal surgery in two fetuses/doe. On day 28/31, the fetuses were randomly instilled with intratracheal PFOB (CDH-PFOB) or saline (CDH-saline). After term delivery, the fetuses were ventilated (30min) and lung-mechanics were measured. Lung-to-body-weight-ratio (LBWR) and mRNA levels of different proteins were determined. Non-operated littermates served as controls. Gene expression was expressed as fold-induction relative to controls.

Results LBWR showed an increase in CDH-PFOB as compared to CDH-saline (p=0.05). Total lung capacity (TLC), static lung compliance (Cst), and RTq-PCR are shown below (+p<0.05 as compared to control, *p<0.05 as compared to CDH-saline):

Abstract 234 Table 1

Conclusions In contrast to previous data addressing tracheal occlusion, PFOB improved TLC and Cst. PFOB also resulted in normalization of Surfactantproteins without inducing extracellularmatrix proteins. Thus, PFOB instillation appears to be a promising therapy for use in fetal lung hypoplasia.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.